Zenas BioPharma (NASDAQ:ZBIO) Trading 10.8% Higher – Still a Buy?

Zenas BioPharma, Inc. (NASDAQ:ZBIO)’s stock price traded up 10.8% on Friday . The company traded as high as $19.19 and last traded at $19.6850. 236,622 shares were traded during trading, a decline of 71% from the average session volume of 803,402 shares. The stock had previously closed at $17.76.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Morgan Stanley upped their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Guggenheim upped their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Finally, Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and an average target price of $44.29.

Zenas BioPharma Trading Up 11.5%

The firm’s 50-day simple moving average is $19.44 and its 200 day simple moving average is $24.67. The stock has a market cap of $1.25 billion, a P/E ratio of -2.34 and a beta of -0.71. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter last year, the business earned ($0.80) earnings per share. As a group, equities research analysts anticipate that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.

Insider Transactions at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of Zenas BioPharma stock in a transaction dated Monday, May 18th. The stock was bought at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the purchase, the chief executive officer owned 96,928 shares in the company, valued at approximately $1,636,144.64. The trade was a 162.48% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Fairmount Funds Management Llc purchased 150,000 shares of Zenas BioPharma stock in a transaction dated Tuesday, March 31st. The stock was bought at an average cost of $20.00 per share, with a total value of $3,000,000.00. Following the completion of the purchase, the director owned 2,359,025 shares in the company, valued at approximately $47,180,500. This trade represents a 6.79% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 273,768 shares of company stock valued at $5,150,198. Company insiders own 22.00% of the company’s stock.

Institutional Trading of Zenas BioPharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its stake in Zenas BioPharma by 723.5% during the first quarter. Bank of America Corp DE now owns 388,347 shares of the company’s stock valued at $7,592,000 after purchasing an additional 341,187 shares during the last quarter. Exome Asset Management LLC acquired a new stake in Zenas BioPharma during the first quarter valued at approximately $1,578,000. Quantinno Capital Management LP acquired a new stake in Zenas BioPharma during the first quarter valued at approximately $413,000. Sei Investments Co. acquired a new stake in Zenas BioPharma during the first quarter valued at approximately $242,000. Finally, Walleye Capital LLC acquired a new stake in Zenas BioPharma during the first quarter valued at approximately $2,448,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.